NASDAQ:BLRX BioLineRx (BLRX) Stock Price, News & Analysis $3.79 +0.11 (+2.99%) Closing price 04:00 PM EasternExtended Trading$3.75 -0.04 (-1.06%) As of 04:59 PM Eastern Extended trading is trading that happens on electronic markets outside of regular trading hours. This is a fair market value extended hours price provided by Polygon.io. Learn more. Add Compare Share Share Stock Analysis Stock AnalysisAnalyst ForecastsChartCompetitorsEarningsHeadlinesOptions ChainOwnershipSEC FilingsShort InterestTrendsBuy This Stock About BioLineRx Stock (NASDAQ:BLRX) 30 days 90 days 365 days Advanced Chart View Price History Chart DataSkip Price History Chart Get BioLineRx alerts:Sign Up Key Stats Today's Range$3.63▼$3.8750-Day Range$2.43▼$3.8052-Week Range$2.30▼$35.60Volume19,295 shsAverage Volume67,682 shsMarket Capitalization$12.62 millionP/E RatioN/ADividend YieldN/APrice Target$26.00Consensus RatingModerate Buy Company OverviewBioLineRx Ltd., a commercial stage biopharmaceutical company, develops and commercializes therapeutics for oncology and rare diseases. The company's pipeline includes APHEXDA (motixafortide), a peptide that is in Phase 1 clinical trial for the treatment of sickle cell disease, and Phase 2b clinical trial for the treatment of pancreatic cancer, as well as completed Phase 3 clinical trial for the treatment of multiple myeloma. It also develops BL-5010, a pen-like applicator containing an acidic aqueous solution for the non-surgical removal of skin lesions. BioLineRx Ltd. was incorporated in 2003 and is headquartered in Hevel Modi'in, Israel.Read More… BioLineRx Stock Analysis - MarketRank™See Top-Rated MarketRank™ Stocks37th Percentile Overall ScoreBLRX MarketRank™: BioLineRx scored higher than 37% of companies evaluated by MarketBeat, and ranked 730th out of 932 stocks in the medical sector. Scores are calculated by averaging available category scores, with extra weight given to analysis and valuation. Analyst's Opinion3.3 / 5Analyst RatingModerate Buy Consensus RatingBioLineRx has received a consensus rating of Moderate Buy. The company's average rating score is 2.50, and is based on 1 buy rating, 1 hold rating, and no sell ratings.Amount of Analyst CoverageBioLineRx has only been the subject of 2 research reports in the past 90 days.Read more about BioLineRx's stock forecast and price target. Earnings and Valuation1.3 / 5Proj. Earnings GrowthGrowing Earnings GrowthEarnings for BioLineRx are expected to grow in the coming year, from ($5.80) to ($5.60) per share.Price to Earnings Ratio vs. the MarketThe P/E ratio of BioLineRx is -0.42, which means that its earnings are negative and its P/E ratio cannot be compared to companies with positive earnings.Price to Earnings Ratio vs. SectorThe P/E ratio of BioLineRx is -0.42, which means that its earnings are negative and its P/E ratio cannot be compared to companies with positive earnings.Price to Book Value per Share RatioBioLineRx has a P/B Ratio of 0.51. P/B Ratios below 1 indicate that a company could be undervalued with respect to its assets and liabilities.Read more about BioLineRx's valuation and earnings. Short Interest3.0 / 5Short Interest LevelHealthy Percentage of Shares Shorted5.37% of the float of BioLineRx has been sold short.Short Interest Ratio / Days to CoverBioLineRx has a short interest ratio ("days to cover") of 5.1.Change versus previous monthShort interest in BioLineRx has recently decreased by 8.47%, indicating that investor sentiment is improving significantly. Dividend0.0 / 5Dividend StrengthN/A Dividend YieldBioLineRx does not currently pay a dividend.Dividend GrowthBioLineRx does not have a long track record of dividend growth. Sustainability and ESGN/AEnvironmental ScoreN/A Percentage of Shares Shorted5.37% of the float of BioLineRx has been sold short.Short Interest Ratio / Days to CoverBioLineRx has a short interest ratio ("days to cover") of 5.1.Change versus previous monthShort interest in BioLineRx has recently decreased by 8.47%, indicating that investor sentiment is improving significantly. News and Social Media1.6 / 5News Sentiment-0.19 News SentimentBioLineRx has a news sentiment score of -0.19. This score is calculated as an average of sentiment of articles about the company over the last seven days and ranges from 2 (good news) to -2 (bad news). This is a lower news sentiment than the 1.03 average news sentiment score of Medical companies.News Coverage This WeekMarketBeat has tracked 9 news articles for BioLineRx this week, compared to 1 article on an average week.Search InterestOnly 1 people have searched for BLRX on MarketBeat in the last 30 days. This is a decrease of 0% compared to the previous 30 days.MarketBeat Follows1 people have added BioLineRx to their MarketBeat watchlist in the last 30 days. Company Ownership0.0 / 5Insider TradingN/A Insider Buying vs. Insider SellingIn the past three months, BioLineRx insiders have not sold or bought any company stock.Percentage Held by InsidersOnly 1.10% of the stock of BioLineRx is held by insiders.Percentage Held by InstitutionsOnly 1.56% of the stock of BioLineRx is held by institutions.Read more about BioLineRx's insider trading history. Receive BLRX Stock News and Ratings via Email Sign-up to receive the latest news and ratings for BioLineRx and its competitors with MarketBeat's FREE daily newsletter. Email Address BLRX Stock News HeadlinesBioLineRx Ltd. (NASDAQ:BLRX) Q1 2025 Earnings Call TranscriptMay 28 at 9:48 AM | insidermonkey.comBioLineRx Ltd.: BioLineRx Reports First Quarter 2025 Financial Results and Provides Corporate UpdateMay 28 at 2:34 AM | finanznachrichten.deA grave, grave error.I thought what happened 25 years ago was a once- in-a-lifetime event… but how wrong I was. Because here we are, a quarter of a century later, almost to the exact day, and it’s happening again. May 28, 2025 | Porter & Company (Ad)BioLineRx Ltd. Reports Q1 2025 Financial ResultsMay 28 at 12:42 AM | tipranks.comBioLineRx Ltd. (BLRX) Q1 2025 Earnings Call TranscriptMay 27 at 1:21 PM | seekingalpha.comBioLineRx Reports Q1 2025 Financial Results and Strategic UpdatesMay 27 at 7:40 AM | tipranks.comBioLineRx Reports First Quarter 2025 Financial Results and Provides Corporate UpdateMay 27 at 7:00 AM | prnewswire.comBioLineRx to Report First Quarter 2025 Results on May 27, 2025May 20, 2025 | prnewswire.comSee More Headlines BLRX Stock Analysis - Frequently Asked Questions How have BLRX shares performed this year? BioLineRx's stock was trading at $8.56 at the beginning of 2025. Since then, BLRX shares have decreased by 56.8% and is now trading at $3.70. View the best growth stocks for 2025 here. How were BioLineRx's earnings last quarter? BioLineRx Ltd. (NASDAQ:BLRX) announced its earnings results on Tuesday, May, 27th. The biotechnology company reported $1.39 earnings per share for the quarter, beating analysts' consensus estimates of ($0.84) by $2.23. The biotechnology company had revenue of $11.75 million for the quarter, compared to the consensus estimate of $7.72 million. BioLineRx had a negative trailing twelve-month return on equity of 163.37% and a negative net margin of 90.57%. Read the conference call transcript. When did BioLineRx's stock split? BioLineRx shares reverse split on the morning of Thursday, January 30th 2025. The 1-40 reverse split was announced on Friday, January 17th 2025. The number of shares owned by shareholders was adjusted after the closing bell on Wednesday, January 29th 2025. An investor that had 100 shares of stock prior to the reverse split would have 3 shares after the split. How do I buy shares of BioLineRx? Shares of BLRX stock can be purchased through any online brokerage account. Popular online brokerages with access to the U.S. stock market include Charles Schwab, E*TRADE, Fidelity, and Vanguard Brokerage Services. What other stocks do shareholders of BioLineRx own? Based on aggregate information from My MarketBeat watchlists, some other companies that BioLineRx investors own include Savara (SVRA), NVIDIA (NVDA), Sorrento Therapeutics (SRNE), Advanced Micro Devices (AMD), Meta Platforms (META), Brainstorm Cell Therapeutics (BCLI) and Tesla (TSLA). Company Calendar Last Earnings11/25/2024Today5/28/2025Next Earnings (Estimated)8/15/2025Fiscal Year End12/31/2025Get Stock AlertsIndustry, Sector and Symbol Stock ExchangeNASDAQ SectorMedical Industry Pharmaceutical preparations Sub-IndustryPharmaceutical Products Current SymbolNASDAQ:BLRX CIK1498403 Webwww.biolinerx.com Phone(728) 642-9100Fax972-8642-9101Employees40Year FoundedN/APrice Target and Rating Average Stock Price Target$26.00 High Stock Price Target$26.00 Low Stock Price Target$26.00 Potential Upside/Downside+606.5%Consensus RatingModerate Buy Rating Score (0-4)2.50 Research Coverage2 Analysts Profitability EPS (Most Recent Fiscal Year)($8.80) Trailing P/E RatioN/A Forward P/E RatioN/A P/E GrowthN/ANet Income-$60.61 million Net Margins-90.57% Pretax Margin-90.57% Return on Equity-163.37% Return on Assets-34.21% Debt Debt-to-Equity Ratio2.11 Current Ratio1.52 Quick Ratio1.37 Sales & Book Value Annual Sales$28.94 million Price / Sales0.42 Cash FlowN/A Price / Cash FlowN/A Book Value$7.30 per share Price / Book0.50Miscellaneous Outstanding Shares3,329,000Free Float3,292,000Market Cap$12.25 million OptionableOptionable Beta1.15 10 Best Cheap Stocks to Buy NowMarketBeat just released its list of 10 cheap stocks that have been overlooked by the market and may be seriously undervalued. Enter your email address and below to see which companies made the list.Get This Free Report This page (NASDAQ:BLRX) was last updated on 5/28/2025 by MarketBeat.com Staff From Our PartnersJuly 2025 Rule Change to Impact Retirement InvestorsThere's a massive change from a new rule going into effect this July. And it's one the Big Banks are alread...Premier Gold Co | SponsoredF1 Engineering Powers This Electric Marine MotorThe future of marine propulsion has arrived - powered by F-1 grade engineering. In collaboration with McLar...The Tomorrow Investor | SponsoredTrump Makes Major Crypto AnnouncementYou Won’t Get a Second Chance at This Entry The crypto comeback isn't coming—it's already here. And one ...Crypto 101 Media | SponsoredMarket Panic: Trump Just Dropped a Bomb on Your Stockstock Market Panic: Trump Just Dropped a Bomb on Your Stocks The market is in freefall—and Trump's new tarif...American Alternative | SponsoredTrump Predicts Dollar DownfallREAD THIS VERY CAREFULLY: If you have $100,000 or more saved for retirement, this may make you VERY angry... ...Augusta Precious Metals | SponsoredTrump Quietly Planning $15 Trillion Crypto ShockerMost investors are still unaware, but I believe a new White House action may have quietly opened the floodgate...Paradigm Press | SponsoredWhite House to reset Social Security?Elon Musk's parting DOGE gift looks set to shock America... A single announcement by July 22nd could soon b...Altimetry | SponsoredIs President Trump Lying To You With This?President Trump’s economic transition isn’t without hardship. But what if there were a smart, tax-free way to ...Colonial Metals | Sponsored Adding Choose a watchlist: Watchlist Adding You have already added five stocks to your watchlist. Upgrade to MarketBeat All Access to add more stocks to your watchlist. Adding BioLineRx Ltd. Please log in to your account or sign up in order to add this asset to your watchlist. Share BioLineRx With A Colleague Link copied to clipboard. Get 30 Days of MarketBeat All Access for Free Sign up for MarketBeat All Access to gain access to MarketBeat's full suite of research tools. Start Your 30-Day Trial MarketBeat All Access Features Best-in-Class Portfolio Monitoring Get personalized stock ideas. Compare portfolio to indices. Check stock news, ratings, SEC filings, and more. Stock Ideas and Recommendations See daily stock ideas from top analysts. Receive short-term trading ideas from MarketBeat. Identify trending stocks on social media. Advanced Stock Screeners and Research Tools Use our seven stock screeners to find suitable stocks. Stay informed with MarketBeat's real-time news. Export data to Excel for personal analysis. Sign in to your free account to enjoy these benefits In-depth profiles and analysis for 20,000 public companies. Real-time analyst ratings, insider transactions, earnings data, and more. Our daily ratings and market update email newsletter. Sign in to your free account to enjoy all that MarketBeat has to offer. Sign In Create Account Your Email Address: Email Address Required Your Password: Password Required Log In or Sign in with Facebook Sign in with Google Forgot your password? Your Email Address: Please enter your email address. Please enter a valid email address Choose a Password: Please enter your password. Your password must be at least 8 characters long and contain at least 1 number, 1 letter, and 1 special character. Create My Account (Free) or Sign in with Facebook Sign in with Google By creating a free account, you agree to our terms of service. This site is protected by reCAPTCHA and the Google Privacy Policy and Terms of Service apply.